Skip to Content Skip to Search

Our pipeline

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients and payers.

 

Our medicines and vaccines in development are classified into three stages: phase I, phase II and phase III. These studies into the safety and efficacy of investigational products provide data to support applications to regulators for approval.

 

The content of our development pipeline will change over time as new projects progress from research to development and from development to the market.

 

For competitive reasons, new projects in pre-clinical development are not disclosed and some project types may not be identified.

 

Brand names are trademarks either owned by and/or licensed to GSK or associated companies.

 

This information was updated on 27 April 2022.

 

For COVID-19 vaccines, GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations.

Download full pipeline in XLSX

XLSX - 24.4KB

Key

In-licence or other alliance relationship with third party
^
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
Ɨ
GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations
*
In a Phase 1/2 study
1
Non-registrational
2
Transition activities underway to enable further progression by partner
3
Approved in Canada
4
GSK has exclusive option to co-develop post Ph2

Pipeline updated 27 April 2022

  • Additional indication
  • Immuno-modulator

Key

In-licence or other alliance relationship with third party
^
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
Ɨ
GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations
*
In a Phase 1/2 study
1
Non-registrational
2
Transition activities underway to enable further progression by partner
3
Approved in Canada
4
GSK has exclusive option to co-develop post Ph2

Q4 2021 to Q1 2022

Key

In-licence or other alliance relationship with third party
^
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
Ɨ
GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations
*
In a Phase 1/2 study
1
Non-registrational
2
Transition activities underway to enable further progression by partner
3
Approved in Canada
4
GSK has exclusive option to co-develop post Ph2
  • Additional indication
  • Immuno-modulator

No results - Please try with another term